Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma

Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uta Casper(Medizinische Hochschule Hannover), Frank Matiaske(Medizinische Hochschule Hannover), Susanne Mommert(Medizinische Hochschule Hannover)

International Journal of Cancer

January 18, 1999

10.1002/(sici)1097-0215(19990118)80:2<205::aid-ijc8>3.0.co;2-j

Cited by 38

Related Papers

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

|Science|2015|3k

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2012|3k

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

|New England Journal of Medicine|2018|1.9k

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

|The Lancet Oncology|2018|1k

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

|The Lancet Oncology|2016|704